Last reviewed · How we verify
Memantine Oral Tablet
Memantine Oral Tablet is a NMDA receptor antagonist Small molecule drug developed by First Affiliated Hospital Xi'an Jiaotong University. It is currently FDA-approved for Moderate to severe Alzheimer's disease. Also known as: Memantine, pioglitazone, hippocampal avoidance whole-brain radiotherapy (HA-WBRT), Namenda.
Memantine is an uncompetitive antagonist of the N-methyl-D-aspartate (NMDA) receptor that reduces excessive glutamatergic neurotransmission in the brain.
Memantine is an uncompetitive antagonist of the N-methyl-D-aspartate (NMDA) receptor that reduces excessive glutamatergic neurotransmission in the brain. Used for Moderate to severe Alzheimer's disease.
At a glance
| Generic name | Memantine Oral Tablet |
|---|---|
| Also known as | Memantine, pioglitazone, hippocampal avoidance whole-brain radiotherapy (HA-WBRT), Namenda, Namenda XR |
| Sponsor | First Affiliated Hospital Xi'an Jiaotong University |
| Drug class | NMDA receptor antagonist |
| Target | NMDA receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
Memantine blocks the NMDA receptor ion channel in a use-dependent manner, allowing it to preferentially inhibit pathological overactivation of glutamate signaling while preserving normal synaptic transmission. This mechanism reduces excitotoxicity and neuronal damage associated with excessive calcium influx. It is used to slow cognitive decline in moderate to severe Alzheimer's disease by protecting neurons from glutamate-mediated injury.
Approved indications
- Moderate to severe Alzheimer's disease
Common side effects
- Dizziness
- Headache
- Constipation
- Confusion
- Hypertension
Key clinical trials
- Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial (PHASE2, PHASE3)
- Satisfaction With Orodispersible vs Conventional Memantine in Moderate to Severe Alzheimer's Disease (PHASE4)
- Masitinib in Patients With Mild Alzheimer's Disease (PHASE3)
- Evaluation of Memantine in the Preservation of Memory and Neurocognition Following CSI (PHASE3)
- "The Effect of Memantine on the Prevention and Amelioration of Paclitaxel-induced Toxicity in Breast Cancer Patients" (PHASE2)
- Early Application of Memantine and Pioglitazone to Protect Cognitive Function After Radiotherapy (PHASE2)
- Study in Healthy Subjects to Compare Two Tablet Formulations of Memantine (Ebixa®) in Fasted and Fed Conditions (PHASE1)
- Masitinib in Patients With Mild to Moderate Alzheimer's Disease (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Memantine Oral Tablet CI brief — competitive landscape report
- Memantine Oral Tablet updates RSS · CI watch RSS
- First Affiliated Hospital Xi'an Jiaotong University portfolio CI
Frequently asked questions about Memantine Oral Tablet
What is Memantine Oral Tablet?
How does Memantine Oral Tablet work?
What is Memantine Oral Tablet used for?
Who makes Memantine Oral Tablet?
Is Memantine Oral Tablet also known as anything else?
What drug class is Memantine Oral Tablet in?
What development phase is Memantine Oral Tablet in?
What are the side effects of Memantine Oral Tablet?
What does Memantine Oral Tablet target?
Related
- Drug class: All NMDA receptor antagonist drugs
- Target: All drugs targeting NMDA receptor
- Manufacturer: First Affiliated Hospital Xi'an Jiaotong University — full pipeline
- Therapeutic area: All drugs in Neurology
- Indication: Drugs for Moderate to severe Alzheimer's disease
- Also known as: Memantine, pioglitazone, hippocampal avoidance whole-brain radiotherapy (HA-WBRT), Namenda, Namenda XR
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing